Skip to main content
U.S. Edition
Tuesday, January 25, 2022

Thursday 11/18 Insider Buying Report: SRPT, DKNG

Duration: 00:54s 0 shares 1 views

Thursday 11/18 Insider Buying Report: SRPT, DKNG
Thursday 11/18 Insider Buying Report: SRPT, DKNG

Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned cash to make a purchase, is that they expect to make money.

Today we look at two noteworthy recent insider buys.

Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned cash to make a purchase, is that they expect to make money.

Today we look at two noteworthy recent insider buys.

On Wednesday, Sarepta Therapeutics' CEO, Douglas S.

Ingram, made a $2.00M buy of SRPT, purchasing 25,026 shares at a cost of $79.94 a piece.

Ingram was up about 3.1% on the buy at the high point of today's trading session, with SRPT trading as high as $82.44 in trading on Thursday.

Sarepta Therapeutics is trading up about 1.9% on the day Thursday.

This buy marks the first one filed by Ingram in the past year.

And on Tuesday, Director Harry Sloan bought $1.98M worth of DraftKings, buying 50,000 shares at a cost of $39.52 a piece.

DraftKings is trading off about 1.7% on the day Thursday.

Bargain hunters have the opportunity to buy DKNG even cheaper than Sloan did, with shares changing hands as low as $37.21 at last check today which is 5.8% below Sloan's purchase price.

You might like